Susanna Fletcher Greer, Chief Scientific Officer of the V Foundation, shared Tony Wells’s post on LinkedIn, adding:
“Thrilled to see reflections like this one by Tony Wells from yesterday’s the V Foundation Conversations for a Cure in Phoenix.
What stays with me after these conversations is how much progress in cancer comes down to two things: better questions and the people willing to ask them.
Dr. Kaitlin Basham’s work reminds us that cancer doesn’t happen in isolation. It is shaped over time by the interplay of aging, genetics, and the environment. If we want to intervene earlier and more effectively, we have to understand that full picture.
Dr. Sarah Adams brought it back to patients. No two cancers are the same, and no two patients are the same. The future of cancer care depends on learning from each individual tumor and using that knowledge to guide treatment in a more precise and thoughtful way.
This is exactly why we invest in high risk, high reward science. The kind of work that pushes beyond what we already know and moves us closer to treatments that are not just better, but truly tailored to the person in front of us.
The need is still urgent. But so is our momentum!
Thank you Phoenix for being part of it.”
Tony Wells, Venture Partner at Copper Sky Capital, shared a post on LinkedIn:
“I had the privilege of attending the V Foundation for Cancer Research event today led by Chief Scientific Officer Susanna Fletcher Greer, Ph.D. , and I left both inspired and reminded of the urgency of the fight ahead.
The numbers are sobering: nearly 2.1 million Americans will be diagnosed with cancer this year, and more than 625,000 will lose their lives. Cancer remains the second leading cause of death in the U.S. – responsible for 1 in 4 deaths. Behind those statistics are families, stories, and futures at stake.
What stood out most, however, was the work of two remarkable researchers Kaitlin Basham, PhD and Sarah Adams, MD who are advancing breakthroughs in adrenal and ovarian cancer.
Kaitlin shared a new model to better understand how aging, genetics, environment, and stress interact to drive adrenal cancer. It’s a powerful reminder that cancer is not a single disease but a complex system influenced by multiple variables that we are only beginning to fully understand.
Sarah emphasized a critical truth: every patient’s cancer is different. The future of treatment lies in precision and understanding the tumor microenvironment, patient-specific factors, and learning directly from clinical outcomes to tailor therapies more effectively.
This is where investment matters. Research like this is what turns insight into innovation, and innovation into survival.
The mission is clear: more personalized, more effective treatments that give patients real hope.
I’m grateful to support organizations like the V Foundation and the scientists pushing this work forward. The progress is real, but so is the need.”
More posts featuring Susanna Fletcher Greer.